New RNA Switch Technology Allows Drugs to Control Gene Therapy Protein Production
Bioengineers at the University of California San Diego have developed a novel RNA switch called an adaptamer, enabling small-molecule drugs to precisely regulate therapeutic protein production in cells.
🏥Public HealthPhoto: Medical Xpress
Key points
- UC San Diego bioengineers developed RNA 'adaptamers' to control gene therapy protein output.
- The switch uses small-molecule drugs to activate or reduce protein production without altering the gene therapy itself.
- Preclinical tests successfully reversed liver fat buildup and promoted weight loss using the metabolic protein FGF21.
Researchers at the University of California San Diego have created a new technology designed to make gene therapies safer and more adaptable. Led by bioengineering professor Prashant Mali and Ph.D. student Jack Bryant, the team developed short pieces of RNA known as adaptamers, short for ADAR-modulatable aptamers. These tools use small-molecule drugs to control when and how much cells produce therapeutic proteins.
Gene therapies typically deliver permanent genetic instructions to cells, which can make it difficult to manage protein levels over time. Because many therapeutic proteins carry risks if expressed at excessive levels or for too long, this new method offers a potential solution by letting clinicians adjust drug dosing to raise or lower protein output without removing the gene therapy.
In preclinical studies published in Molecular Cell, the team tested the adaptamer system to regulate the production of FGF21, a metabolic protein that helps combat obesity. The experiments showed that drug-activated protein production led to significant weight loss, better blood sugar regulation, and a near-complete reversal of liver fat accumulation. However, researchers emphasize that these findings are early-stage preclinical results, and further study is required to determine how precisely protein levels can be fine-tuned in clinical settings.
What to know: The adaptamer system acts as an adjustable molecular switch, using drugs like tetracycline or doxycycline to turn therapeutic protein production on or off as a patient's medical needs change. Always consult a qualified healthcare provider for personal medical decisions and advice regarding treatments.
Source Medical Xpress — medicalxpress.com/news/2026-11-rna-drugs-gene-therapy-protein.html ↗
Read next
🏃FitnessUnderstanding and Addressing Love Handles Through Lifestyle Changes
Experts clarify that spot reduction of fat is not physiologically possible, recommending a combination of calorie management and high-intensity interval training instead.
🏃FitnessCiele Releases New Woolmark-Certified Merino Winter Running Apparel
Montreal-based brand Ciele has launched its second collection of merino wool running gear, featuring performance-focused fabrics designed for cold-weather training.
❤️Conditions & CareBlood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma
Researchers have identified a specific RNA signature in blood plasma that may help predict how well lymphoma patients respond to CAR T-cell therapy.
🧠AI AnalysisUltraprocessed Diets May Impact Brain Reward Systems in Younger Adults
A Virginia Tech study suggests that individuals aged 18 to 21 may experience changes in brain reward processing after consuming ultraprocessed foods, a response not obser…
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
❤️Conditions & CareMigraine and Smoking Linked to Increased Early Stroke Risk in Women
A large-scale study suggests that people who have given birth and experience migraines while also smoking face a significantly higher risk of stroke before age 60.